Innovent reports Chinese NET, NSCLC data for PD-1 mAb

Innovent Biologics Inc. (Suzhou, China) presented data this week from neuroendocrine tumor and non-small cell lung cancer cohorts in its Chinese Phase Ib trial of anti-PD-1 mAb sintilimab (IBI308). Data were presented at the Chinese Society of Clinical Oncology meeting in Xiamen.

On Thursday, Innovent said sintilimab led to an ORR of 22.7% in 22 evaluable NET patients who failed standard therapy. In 19 evaluable patients with poorly differentiated neuroendocrine carcinoma, sintilimab led to an ORR of 26.3%. As of a June 28 data cutoff, median duration of response was 5.8 months and progression-free survival (PFS) was 2.2 months. Median overall survival (OS) had not yet been reached...